KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.79
+1.13%Margins
Gross margin
95.9%
EBITDA margin
-120.0%
EBIT margin
-56.2%
Net margin
-153.3%
FCF margin
-44.6%
68.1%
Return on equity
-201.9%
Return on assets
72.1%
Return on invested capital
1.21x
Asset turnover
-$65.3M
Cash from operations
$2.87
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026